Glenmark Drug Patent Portfolio
Glenmark owns 1 orange book drug protected by 16 US patents Given below is the list of Glenmark's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12303635 | Dispensing device and pharmaceutical composition for the treatment of rhinitis | 08 Apr, 2039 | Active |
| US11679210 | Dispensing device and pharmaceutical composition for the treatment of rhinitis | 03 Sep, 2038 | Active |
| US10016443 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | 04 Sep, 2034 | Active |
| US10376526 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | 04 Sep, 2034 | Active |
| US10517880 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | 04 Sep, 2034 | Active |
| US10548907 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | 04 Sep, 2034 | Active |
| US10561672 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | 04 Sep, 2034 | Active |
| US10646500 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | 04 Sep, 2034 | Active |
| US10758550 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | 04 Sep, 2034 | Active |
| US10765686 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | 04 Sep, 2034 | Active |
| US11400101 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | 04 Sep, 2034 | Active |
| US12064442 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine | 04 Sep, 2034 | Active |
| US9078923 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | 04 Sep, 2034 | Active |
| US9370483 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | 04 Sep, 2034 | Active |
| US9750754 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | 04 Sep, 2034 | Active |
| US9937189 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine | 04 Sep, 2034 | Active |
Latest Legal Activities on Glenmark's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Glenmark.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Feb, 2024 | US10765686 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Feb, 2024 | US10758550 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Dec, 2023 | US9370483 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 25 Oct, 2023 | US10646500 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 02 Aug, 2023 | US10561672 |
| Post Issue Communication - Certificate of Correction | 31 Jul, 2023 | US10016443 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Jul, 2023 | US10548907 |
|
Email Notification
Critical
| 29 Jun, 2023 | US10016443 |
|
Electronic Review
Critical
| 29 Jun, 2023 | US10016443 |
| Mail Pet Dec Routed to Certificate of Corrections Branch | 28 Jun, 2023 | US10016443 |
| Mail-Record a Petition Decision of Granted to Issue Patent in Name of the Assignee | 28 Jun, 2023 | US10016443 |
| Record a Petition Decision of Granted to Issue Patent in Name of the Assignee | 27 Jun, 2023 | US10016443 |
| Pet Dec Routed to Certificate of Corrections Branch | 27 Jun, 2023 | US10016443 |
|
Email Notification
Critical
| 23 Jun, 2023 | US10758550 |
|
Electronic Review
Critical
| 23 Jun, 2023 | US10758550 |
Glenmark Drug Patents' Oppositions Filed in EPO
Glenmark drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Mar 29, 2022, by Ter Meer Steinmeister & Partner Patentanwälte Mbb. This opposition was filed on patent number EP14781946A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP14781946A | Mar, 2022 | Ter Meer Steinmeister & Partner Patentanwälte mbB | Granted and Under Opposition |
Glenmark's Family Patents
Glenmark drugs have patent protection in a total of 32 countries. It's US patent count contributes only to 20.8% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Recent FDA approvals and tentative approvals for Glenmark
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Saxagliptin |
ORIG-2
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 15 Feb, 2023 |
| Nintedanib |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 22 Jun, 2021 |
| Gabapentin Encarbil |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 29 Dec, 2020 |
Glenmark Drug List
Given below is the complete list of Glenmark's drugs and the patents protecting them.
1. Ryaltris
Ryaltris is protected by 16 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12303635 | Dispensing device and pharmaceutical composition for the treatment of rhinitis |
08 Apr, 2039
(13 years from now)
| Active |
| US11679210 | Dispensing device and pharmaceutical composition for the treatment of rhinitis |
03 Sep, 2038
(12 years from now)
| Active |
| US10016443 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
04 Sep, 2034
(8 years from now)
| Active |
| US10376526 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
04 Sep, 2034
(8 years from now)
| Active |
| US10517880 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
04 Sep, 2034
(8 years from now)
| Active |
| US10548907 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
04 Sep, 2034
(8 years from now)
| Active |
| US10561672 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
04 Sep, 2034
(8 years from now)
| Active |
| US10646500 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
04 Sep, 2034
(8 years from now)
| Active |
| US10758550 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
04 Sep, 2034
(8 years from now)
| Active |
| US10765686 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
04 Sep, 2034
(8 years from now)
| Active |
| US11400101 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
04 Sep, 2034
(8 years from now)
| Active |
| US12064442 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
04 Sep, 2034
(8 years from now)
| Active |
| US9078923 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
04 Sep, 2034
(8 years from now)
| Active |
| US9370483 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
04 Sep, 2034
(8 years from now)
| Active |
| US9750754 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
04 Sep, 2034
(8 years from now)
| Active |
| US9937189 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
04 Sep, 2034
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ryaltris's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List